CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 04/01/24
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare InvestorsGlobeNewsWire • 03/28/24
CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024GlobeNewsWire • 03/05/24
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy BodiesGlobeNewsWire • 02/12/24
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the BoardGlobeNewsWire • 02/07/24
CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy BodiesPRNewsWire • 10/25/23
CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major DementiasPRNewsWire • 10/24/23
CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy BodiesPRNewsWire • 10/18/23